囊性纤维化患者的性别肯定激素治疗——一例新发铜绿假单胞菌感染病例

Gender-affirming hormone therapy in cystic fibrosis - A case of new Pseudomonas infection.

作者信息

Shaffer L, Bozkanat K, Lau M, Sharma P, Sathe M, Lopez X, Jain R

机构信息

University of Texas Southwestern Medical Center, Dallas, TX, USA.

Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.

出版信息

Respir Med Case Rep. 2021 Jan 21;32:101353. doi: 10.1016/j.rmcr.2021.101353. eCollection 2021.

DOI:10.1016/j.rmcr.2021.101353

PMID:33537203

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7841348/

Abstract

BACKGROUND

Little is known about the impact of hormone therapy on transgender youth with Cystic Fibrosis (CF). This case report describes an 18-year-old affirmed female with CF who was treated with hormone therapy associated in timing with new growth of in her sputum culture.

DISCUSSION

We highlight important considerations, including the impact of gender-affirming hormone therapy on overall CF disease course. Evidence supports that females with CF have worse outcomes than males, which are partly attributed to estrogen effects. is one of the most prevalent pathogens in people with CF. Here, we highlight a transfemale who grows for the first time since her youth, nearly 1 year after starting estrogen therapy. This is consistent with previous literature of an association between high estrogen levels and prevalence, but has never been evaluated in a transgender population.

CONCLUSION

Through this case, we demonstrate the need for additional research to understand the relationship between gender-affirmative hormone transition and CF care and management.

摘要

背景

关于激素疗法对患有囊性纤维化（CF）的跨性别青少年的影响，目前所知甚少。本病例报告描述了一名18岁确诊为女性的CF患者，其在痰培养中出现新的[具体病原体名称未给出]生长时接受了激素治疗。

讨论

我们强调了重要的考虑因素，包括性别确认激素疗法对CF整体病程的影响。有证据表明，患有CF的女性比男性预后更差，部分原因是雌激素的作用。[具体病原体名称未给出]是CF患者中最常见的病原体之一。在此，我们突出了一名跨性别女性，自青少年时期以来首次在开始雌激素治疗近1年后培养出[具体病原体名称未给出]。这与之前关于高雌激素水平与[具体病原体名称未给出]患病率之间关联的文献一致，但从未在跨性别群体中进行过评估。